Researcher profile

David B. Ascher

David B. Ascher contributes to research discovery and scholarly infrastructure.

ResearcherAffiliation not importedOpen to collaborate

Computation and Language Genomics Machine Learning Molecular Networks

Trust snapshot

Quick read

Trust 15 - UnverifiedVerification L1Unclaimed author

3works

0followers

4topics

3close collaborators

Actions

Decide how to stay connected

Follow researcher0

Claiming links this public author record to a researcher profile and unlocks direct collaboration workflows.

Direct collaboration

Open a focused conversation when the fit is right

Claim this author entity first to unlock direct invitations.

Inspect adjacent work, topics, institutions and collaborators without jumping out to a separate graph page.

Building this graph slice

BZPEER is loading the nearby papers, people, topics and institutions for this page.

preprint2026arXiv

EFGPP: Exploratory framework for genotype-phenotype prediction

Predicting complex human traits from genetic data is challenging because different genetic, clinical, and molecular data sources often contain different parts of the signal. Here, we present EFGPP, a reproducible framework for generating, ranking, and combining multiple types of data for genotype-to-phenotype prediction. We applied EFGPP to migraine prediction using UK Biobank data from 733 individuals. The framework combined genotype-derived features, principal components, clinical and metabolomic covariates, and polygenic risk scores generated from migraine and depression GWAS using PLINK, PRSice-2, AnnoPred, and LDAK-GWAS. The best single data type achieved a test AUC of 0.644, while combining multiple data types improved performance to 0.688 using migraine-focused inputs and 0.663 using cross-trait depression-derived inputs. Genetic features alone did not outperform the covariates-only baseline, but genotype-derived features performed better than PRS alone, and depression-derived PRS showed useful predictive signal. Overall, EFGPP provides a practical proof-of-concept framework for prioritising and integrating heterogeneous genetic data sources for complex phenotype prediction.

preprint2025arXiv

An Empirical Analysis of Fine-Tuning Large Language Models on Bioinformatics Literature: PRSGPT and BioStarsGPT

Large language models (LLMs) often lack specialized knowledge for complex bioinformatics applications. We present a reproducible pipeline for fine-tuning LLMs on specialized bioinformatics data, demonstrated through two use cases: PRSGPT, focused on polygenic risk score (PRS) tools, and BioStarsGPT, trained on community forum discussions. The nine-step pipeline integrates diverse data sources, structured preprocessing, prompt-based question-answer (QA) generation (via Google Gemini), natural language inference (NLI) for quality control, semantic deduplication, clustering-based data splitting, and parameter-efficient fine-tuning using LoRA. We fine-tuned three LLMs (LLaMA-3.2-3B, Qwen2.5-7B, Gemma) and benchmarked them on over 14 lexical and semantic metrics. Qwen2.5-7B emerged as the best performer, with BLEU-4 and ROUGE-1 improvements of 82\% and 70\% for PRSGPT and 6\% and 18\% for BioStarsGPT, respectively. The open-source datasets produced include over 28,000 QA pairs for PRSGPT and 154,282 for BioStarsGPT. Human evaluation of PRSGPT yielded 61.9\% accuracy on the PRS tools comparison task, comparable to Google Gemini (61.4\%), but with richer methodological detail and accurate citations. BioStarsGPT demonstrated 59\% conceptual accuracy across 142 curated bioinformatics questions. Our pipeline enables scalable, domain-specific fine-tuning of LLMs. It enables privacy-preserving, locally deployable bioinformatics assistants, explores their practical applications, and addresses the challenges, limitations, and mitigation strategies associated with their development and use.

preprint2021arXiv

Known allosteric proteins have central roles in genetic disease

Allostery is a form of protein regulation, where ligands that bind sites located apart from the active site can modify the activity of the protein. The molecular mechanisms of allostery have been extensively studied, because allosteric sites are less conserved than active sites, and drugs targeting them are more specific than drugs binding the active sites. Here we quantify the importance of allostery in genetic disease. We show that 1) known allosteric proteins are central in disease networks, and contribute to genetic disease and comorbidities much more than non-allosteric proteins, in many major disease types like hematopoietic diseases, cardiovascular diseases, cancers, diabetes, or diseases of the central nervous system. 2) variants from cancer genome-wide association studies are enriched near allosteric proteins, indicating their importance to polygenic traits; and 3) the importance of allosteric proteins in disease is due, at least partly, to their central positions in protein-protein interaction networks, and probably not due to their dynamical properties.

Institution

Affiliation not imported yet

This author record came from a source that does not expose affiliation metadata. Once the author claims the profile or we enrich the record from another provider, this section will link to the concrete institution.

Topic footprint